Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA
MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced the acquisition of Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA for €5.15m in cash and shares.
The acquisition of ANMI significantly expands the market opportunity for Telix’s investment in prostate cancer imaging and builds on the existing commercialization collaboration for the illumetTM prostate imaging (68Ga-PSMA) kit for the US market. Combining the resources, clinical data and human capital of both companies is expected to accelerate the process of preparing a new drug application (NDA) in the United States and Europe for prostate imaging.
Telix CEO Christian Behrenbruch stated, “The acquisition of ANMI creates a significantly more capable company with the ability to deliver prostate cancer imaging on a global basis, rather than in a territorially-segmented manner. The clinical availability of prostate cancer imaging will have a major impact on the adoption rate of PSMA radiotherapeutics and therefore this acquisition reinforces our competitive differentiation of offering both imaging and therapy as an integrated solution. We’re very pleased to welcome the talented ANMI team to Telix.”
ANMI Co-Founder and CEO Ludovic Wouters noted, “ANMI and Telix have achieved a great deal as business partners over the past two years. With the growing importance of nuclear medicine, particularly in urologic oncology, the two companies benefit from establishing an integrated theranostic approach. We also see a clear way for ANMI to contribute to Telix’s product development by packaging their therapeutic products in way that makes them fast and easy to prepare in the radiopharmacy setting.”
The transaction is expected to complete in December 2018. Financial details of the transaction are available: https://www.asx.com.au/asx/share-price-research/company/TLX.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (Japan) and Indianapolis (USA). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.
About Advanced Nuclear Medicine Ingredients (ANMI) SA
ANMI SA is a pharmaceutical company developing innovative radiopharmaceutical solutions and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the scalable synthesis of “theranostic” (therapeutic + diagnostic) radiopharmaceuticals and to ease their daily production in hospitals and radiopharmacies. ANMI's vision is focused on increasing patient access to new highly specific theranostic radiopharmaceuticals through streamlined and cost-effective production processes. For more information visit www.anmi.be.
About Prostate-Specific Membrane Antigen (PSMA)
PSMA is a cancer target (cell surface antigen) that is highly upregulated in prostate cancer cells and is a highly validated and promising target for a range of diagnostic and therapeutic strategies in prostate cancer.
About HBED-CC-PSMA-11 (68Ga-PSMA)
HBED-CC-PSMA-11 (68Ga-PSMA) is a small molecule (ligand) that targets and binds to PSMA and enables metastatic prostate cancer to be imaged using Positron Emission Tomography (PET) with excellent sensitivity and specificity. PET is a highly effective and widely used imaging modality in the management of cancer.
About the 68Ga-PSMA Kit (illumetTM )
ANMI’s 68Ga-PSMA kit is the first “cold kit” for direct labelling of a PSMA-targeting molecule with 68Ga (gallium). The kit utilizes proprietary chemistry to enable robust and reliable radiolabeling at room temperature in 5 minutes. The 68Ga-PSMA kit is currently in late-stage clinical development in Europe and is commercialized in the US by Telix Pharmaceuticals (US) Inc. where it is marked under the brand name illumetTM .
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorization in any jurisdiction, including the United States and Europe.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Atom Power Introduces First Ever Digital Circuit Breaker21.5.2019 15:00:00 CEST | Pressemelding
New technology certified for widespread commercial use, bringing power distribution to the digital age for the first time CHARLOTTE, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- Atom Power, inventor of the world’s first and only digital circuit breaker, today announced its technology is listed by Underwriters Laboratories (UL), the governing standard for consumer safety. This is the first time in the history of commercial power distribution that a digital solid-state circuit breaker has been listed by UL. Circuit breaker technology hasn’t fundamentally changed in more than 140 years. In that time, everything else has — from telegraphs and carriages to smartphones and electric vehicles. Despite massive innovation in renewables, batteries and vehicles, our analog infrastructure hits a series of bottlenecks when these power sources meet at a single point, like a physical structure. “Today, power is plentiful — renewable costs are falling, many structures have generators and batteries store more
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease21.5.2019 14:00:00 CEST | Pressemelding
NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). ABO-202 is designed to deliver a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs using a combined intravenous and intrathecal delivery via the AAV9 vector. The Company will provide guidance on the timing of the clinical trial later this year. “This significant step brings hope to people impacted by this devastating disease and was achieved in partnership with Dr. Steven Gray and Taylor’s Tale,” said Timothy J. Miller, Ph.D., Co-Founder, President & Chief Scientific Officer. “We are very encouraged that ABO-202 wa
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies21.5.2019 12:00:00 CEST | Pressemelding
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics ®, today announces expansion of space and testing capabilities in their international network of accredited LabPMM® clinical laboratories. Additions to the test menu will include morphology, IHC, flow cytometry, as well as the latest multiparameter flow- (MPF), and NGS-based minimal residual disease (MRD) testing of primary specimens. These new services will further support rapid patient diagnosis, study subject enrollment, and study subject stratifications. They will be available by end of this year in San Diego followed by the laboratories in Japan, Germany and China. “Our comprehensive test menu will eliminate the need for partners to split primary specimens, dramatically decreasing turnaround times and accelerating receipt of comprehensive test reports. This is especially important for partners performing international clinical
Canadian Natural Resources Limited Announces Normal Course Issuer Bid21.5.2019 11:00:00 CEST | Pressemelding
CALGARY, Alberta, May 21, 2019 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited ("Canadian Natural") announced today that the Toronto Stock Exchange has accepted notice filed by Canadian Natural of its intention to make a Normal Course Issuer Bid (“NCIB”) through the facilities of the Toronto Stock Exchange or other alternative Canadian trading systems. Purchases may also be made through the facilities of the New York Stock Exchange. The notice provides that Canadian Natural may, during the 12 month period commencing May 23, 2019 and ending May 22, 2020, purchase for cancellation up to 59,729,706 common shares, being 5% of the 1,194,594,136 issued and outstanding common shares as at May 10, 2019. Canadian Natural will not acquire more than 25% of the average daily trading volume of its common shares during a trading day, being 975,709 common shares subject to certain prescribed exceptions. The price which Canadian Natural will pay for any such shares will be the market price at t
Telia Norway signs partner agreement with IMImobile for Enterprise cPaaS offering21.5.2019 09:00:00 CEST | Pressemelding
Scandinavian telecommunications provider to resell IMImobile’s cPaaS offering, IMIconnect, to enterprise customers LONDON, May 21, 2019 (GLOBE NEWSWIRE) -- IMImobile, a global communications software provider, has signed a partner agreement with Telia Norway, with an option to extend to the wider Telia Company – the leading telecom operator in the Nordic/Baltics. The partner agreement will enable Telia to resell IMImobile’s cloud products, including its enterprise cPaaS (Communications Platform as a Service) offering, IMIconnect, to its enterprise customers. IMIconnect enables businesses to rapidly launch and orchestrate two-way, trigger-based customer communications across 10+ channels. Driven by the changes in person to person communications, consumers now expect interactions with businesses to be personalised, relevant, contextual, interactive and conducted in real time. IMImobile is helping Telia to keep pace with changing consumer expectations and offer innovative communications s
GridGain Joins Cloud Native Computing Foundation21.5.2019 09:00:00 CEST | Pressemelding
Increasingly Deployed in the Cloud, GridGain Looks to Contribute to Growing Body of Cloud Native Best Practices FOSTER CITY, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced it has joined the Cloud Native Computing Foundation® (CNCF®) and The Linux Foundation. GridGain is demonstrating its support for the CNCF with a Silver Membership and participating in the foundation’s programs and guidance related to supporting cloud native applications. CNCF is an open source software foundation dedicated to making cloud native computing universal and sustainable. CNCF has over 400 members including the world’s largest public cloud and enterprise software companies as well as dozens of innovative startups. Cloud-native computing uses an open source software stack to deploy applications as microservices, packaging each part into its own container, and dynamically orchestrating those conta